These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 36599263

  • 1. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S, Luo L, Sun X, Yang Y, Guo Q, Jiang Z, Wu Y.
    Bioorg Med Chem; 2023 Jan 15; 78():117133. PubMed ID: 36599263
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X, Zhang B, Luo L, Yang Y, He B, Zhang Q, Wang L, Xu S, Zheng P, Zhu W.
    Bioorg Chem; 2022 Dec 15; 129():106157. PubMed ID: 36209563
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
    Zhang B, Zhang Q, Xiao Z, Sun X, Yang Z, Gu Q, Liu Z, Xie T, Jin Q, Zheng P, Xu S, Zhu W.
    Bioorg Chem; 2020 Jan 15; 95():103525. PubMed ID: 31887474
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
    Zhu W, Chen C, Sun C, Xu S, Wu C, Lei F, Xia H, Tu Q, Zheng P.
    Eur J Med Chem; 2015 Mar 26; 93():64-73. PubMed ID: 25659752
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
    Liao W, Wang Z, Han Y, Qi Y, Liu J, Xie J, Tian Y, Lei Q, Chen R, Sun M, Tang L, Gong G, Zhao Y.
    Eur J Med Chem; 2020 Jul 01; 197():112309. PubMed ID: 32375077
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition.
    Li SS, Chen JJ, Zhang MM, Wang WX, Zhang WY, Ma C.
    Eur J Med Chem; 2024 May 05; 271():116425. PubMed ID: 38636129
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y, Tian Y, Wang R, Fu S, Jiang J, Dong J, Qin M, Hou Y, Zhao Y.
    Bioorg Chem; 2020 Nov 05; 104():104197. PubMed ID: 32927132
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
    Lei F, Sun C, Xu S, Wang Q, OuYang Y, Chen C, Xia H, Wang L, Zheng P, Zhu W.
    Eur J Med Chem; 2016 Jun 30; 116():27-35. PubMed ID: 27043268
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
    Rageot D, Bohnacker T, Keles E, McPhail JA, Hoffmann RM, Melone A, Borsari C, Sriramaratnam R, Sele AM, Beaufils F, Hebeisen P, Fabbro D, Hillmann P, Burke JE, Wymann MP.
    J Med Chem; 2019 Jul 11; 62(13):6241-6261. PubMed ID: 31244112
    [Abstract] [Full Text] [Related]

  • 15. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C, Chen Y, Wu T, Gao Y, Liu X, Yang Y, Ling Y, Jia Y, Deng M, Wang J, Zhou Y.
    Eur J Med Chem; 2023 Oct 05; 258():115543. PubMed ID: 37329712
    [Abstract] [Full Text] [Related]

  • 16. Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors.
    Megally Abdo NY, Milad Mohareb R, Halim PA.
    Bioorg Chem; 2020 Apr 05; 97():103667. PubMed ID: 32087416
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
    Lv X, Ying H, Ma X, Qiu N, Wu P, Yang B, Hu Y.
    Eur J Med Chem; 2015 Jun 24; 99():36-50. PubMed ID: 26046312
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC.
    Wang T, Wang Y, Lu J, Chen J, Wang L, Ouyang Z, Ouyang W, Hu C, Weng J, Zhang JQ.
    Bioorg Chem; 2024 Oct 24; 151():107714. PubMed ID: 39167867
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer.
    Wu CF, Wang QC, Chen R, Zhou HL, Wu TT, Du Y, Zhang NN, Zhang HM, Fan ZY, Wang LL, Hu CJ, Sang ZP, Li HL, Wang L, Tang L, Zhang JQ.
    Eur J Med Chem; 2022 Feb 05; 229():114055. PubMed ID: 34971874
    [Abstract] [Full Text] [Related]

  • 20. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
    Abbas SH, Abd El-Hafeez AA, Shoman ME, Montano MM, Hassan HA.
    Bioorg Chem; 2019 Feb 05; 82():360-377. PubMed ID: 30428415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.